Name Stephen Burley | Role Scientist | |
 | ||
Institutions Rutgers UniversityLilly Research LaboratoriesRockefeller UniversityHoward Hughes Medical Institute Thesis Molecular arrangement in viruses studied by X-ray and neutron scattering and other physical techniques (1983) | ||
Doctoral advisor Dr. Andrew Miller | ||
International Year of Crystallography 2014: A biased history of macromolecular crystallography
Stephen Kevin Burley is a British-born scientist, naturalized in both Canada and the United States, specializing in oncology and structural biology. He is a Distinguished Professor in the Department of Chemistry and Chemical Biology at Rutgers University. Burley directs the RCSB Protein Data Bank (a member of the Worldwide Protein Data Bank) and the Center for Integrative Proteomics Research
Contents
- International Year of Crystallography 2014 A biased history of macromolecular crystallography
- PDB
- Career
- Honors and awards
- References
創薬へのPDBデータバンクのインパクト
Career
Burley has a Bachelor in physics from the University of Western Ontario and is D.Phil from Oxford University, England in Molecular Biophysics as a Rhodes scholar. Burley has an M.D. from Harvard Medical School.
He worked with Gregory A. Petsko and William N. Lipscomb at MIT and Harvard. He was faculty at Howard Hughes Medical Institute and Rockefeller University. Burley co-founded Prospect Genomics, Inc, a computational genomics pharma. He was Chief Scientific Officer of SGX Pharmaceuticals after it acquired Prospect. SGX was in turn merged with Eli Lilly in 2008 where Burley was a Distinguished Lilly Research Scholar in Lilly Research Laboratories
In 2012 Burley joined Rutgers as Director of the Center for Integrative Proteomics Research and became director of the PDB in 2014, succeeding Prof. Helen Berman